Print this page

Video Education with Result Dependent dIsclosure (VERDI)

The overall study objective is to identify and evaluate strategies to improve the accessibility of
the video education with result dependent disclosure (VERDI) model, increasingly utilized as a
pre-genetic testing (pretest) education alternative in clinical practice, to better serve a more
diverse patient population at risk for hereditary cancers.

This developmental work is imperative as the VERDI models utilized at DFCI in research
studies #18-411 (ProActive), #17-409 (ProGen), #19-068 (OPT-IN), and #19-652 (GeneBOPP)
have been overwhelmingly used in DFCI patients of Caucasian ancestry. While DFCI
participants have responded well, in an effort improve the generalizability of VERDI and expand
it to a diverse patient population, qualitative feedback is being sought explicitly from patients
who self-identify as Black and Latinx patients.

A brief qualitative assessment among a small, cohort of English and Spanish speaking Black and
Latinx participants will first be conducted to identify refinements to video education (VE) that
may increase the utility of the VERDI model for patients in these traditionally underserved
populations. Participants in the qualitative assessment study will receive VE exclusively for
pretest education, followed by a short interview with research staff regarding their experiences
with the VE model. The qualitative assessment study will precede a large-scale randomized
controlled trial of VERDI vs standard genetic counseling (SGC), as informed by the results of
the developmental study.

We hypothesize that the data yielded from the completion of the study objectives will assist in
further refining the VERDI model and its use in clinical practices for the purpose of increasing
genetic testing uptake and improving patient outcomes in minority populations that have been
underrepresented in similar research to date.

Protocol Number: 042207
Phase: N/A
Applicable Disease Sites: Pancreas
Melanoma, Skin
Colon
Ovary
Soft Tissue
Prostate
Kidney
Breast
Principal Investigator: Deborah Toppmeyer M.D.
Scope: National
Participating Institutions:
  • Rutgers Cancer Institute of New Jersey
Inclusion & Exclusion Criteria

Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site ClinicalTrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.

For further information about clinical trials, please contact us at 732-235-7356.